Loading…
Dermata Therapeutics, Inc. is projected to rise to $1.13 by 2027, a +5% move from its current price of $1.08. DRMA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.04 | $1.08 | $1.11 | +0.05% |
| Aug 6 | $1.03 | $1.08 | $1.12 | +0.11% |
| Aug 7 | $1.02 | $1.08 | $1.13 | +0.16% |
| Aug 8 | $1.01 | $1.08 | $1.14 | +0.22% |
| Aug 9 | $1.01 | $1.08 | $1.15 | +0.27% |
| Aug 10 | $1.00 | $1.08 | $1.16 | +0.33% |
| Aug 11 | $0.9972 | $1.08 | $1.17 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9972 | $1.08 | $1.17 | +0.38% |
| Week 2 | $0.9688 | $1.08 | $1.21 | +0.77% |
| Week 3 | $0.9485 | $1.09 | $1.25 | +1.16% |
| Week 4 | $0.9322 | $1.09 | $1.28 | +1.54% |
| Week 5 | $0.9185 | $1.10 | $1.31 | +1.93% |
| Week 6 | $0.9066 | $1.10 | $1.33 | +2.33% |
| Week 7 | $0.8961 | $1.10 | $1.36 | +2.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. It is categorized within Healthcare.
Dermata Therapeutics, Inc. (DRMA) is a healthcare stock with a current price of $1.18 and a market cap of $4.75M. It is ranked 5301 by market listings, reflecting its micro-cap positioning in the market.
The current price sits below the 50-day simple moving average of $1.27 and well below the 200-day simple moving average of $1.91, signaling near-term weakness relative to longer-term averages. The stock’s 30-day range spans $0.9573 to $1.45, providing a sense of recent price volatility.
A major floor 6.0% below — a decisive break under it would weaken the trend.
Support has flipped 8.8% overhead — reclaiming it would be bullish.
The nearest ceiling, 31.2% above — a clean break opens room to run.
A major ceiling 44.2% above — clearing it would confirm fresh momentum.
Key DRMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DRMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.21 | Sell | $1.20 | Sell |
| MA 10 | $1.24 | Sell | $1.24 | Sell |
| MA 20 | $1.29 | Sell | $1.26 | Sell |
| MA 50 | $1.27 | Sell | $1.28 | Sell |
| MA 100 | $1.27 | Sell | $1.46 | Sell |
| MA 200 | $1.88 | Sell | $3.11 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.69 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -156.62 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -10.00 | Sell |
| Bollinger %B (20,2) | 0.03 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 31.16 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.16 | Sell |
| ADX (14) | 10.66 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture shows bearish sentiment with momentum softer in the near term. RSI(14) is 40, and the price trading below the SMA50 ($1.27) and SMA200 ($1.91) reinforces a cautious near-term view.
Key support is at $1.17 and resistance at $1.41, framing the immediate risk/reward. The 30-day range extends from $0.9573 to $1.45, highlighting notable intraday movement and volatility with an annualized volatility of 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.08 | $1.08 | $1.42 | 0% | Neutral | |
| $0.8938 | $1.13 | $1.51 | +5% | Neutral | |
| $0.9819 | $1.28 | $1.79 | +19% | Neutral | |
| $1.04 | $1.39 | $2.00 | +29% | Bullish | |
| $1.09 | $1.50 | $2.22 | +39% | Bullish | |
| $1.03 | $1.44 | $2.19 | +34% | Bullish | |
| $0.9072 | $1.29 | $2.00 | +20% | Bullish | |
| $0.9748 | $1.42 | $2.23 | +32% | Bullish | |
| $1.02 | $1.50 | $2.40 | +40% | Bullish | |
| $1.13 | $1.70 | $2.76 | +58% | Bullish | |
| $1.08 | $1.76 | $3.05 | +63% | Bullish | |
| $2.05 | $3.79 | $7.24 | +252% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.08 | $1.08 | $1.27 | +0.00% |
| September 2026 | $0.9261 | $1.10 | $1.34 | +2.12% |
| October 2026 | $0.9461 | $1.13 | $1.40 | +2.93% |
| November 2026 | $0.9257 | $1.11 | $1.39 | -1.55% |
| December 2026 | $0.9368 | $1.13 | $1.42 | +1.77% |
Click any year to see its month-by-month DRMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Dermata Therapeutics, Inc.'s 2026 outlook centres on $1.08, within a $1.08 to $1.42 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, DRMA could reach as high as $1.51, with a base case around $1.13 and support toward $0.8938 — roughly +5% from $1.08. Price action looks broadly range-bound.
Expect DRMA to range from $0.9819 to $1.79 through 2028. The $1.28 average target implies a +19% move from current prices. That is up +13% on the projected 2027 average. A consolidation phase looks the most probable path here.
The DRMA price prediction for 2029 points to an average of $1.39 (low $1.04, high $2.00) — a potential gain of +29% on today's $1.08. Momentum favours further upside here.
In 2030, DRMA is projected to trade between $1.09 and $2.22, averaging $1.50 — a potential gain of +39% from today's $1.08. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Dermata Therapeutics, Inc.'s 2031 outlook centres on $1.44, within a $1.03 to $2.19 range. That is -4% versus the projected 2030 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2032, DRMA could reach as high as $2.00, with a base case around $1.29 and support toward $0.9072 — roughly +20% from $1.08. Buyers look set to stay in control over this stretch.
Expect DRMA to range from $0.9748 to $2.23 through 2033. The $1.42 average target implies a +32% move from current prices. That is up +9% on the projected 2032 average. Momentum favours further upside here.
The DRMA price prediction for 2034 points to an average of $1.50 (low $1.02, high $2.40) — a potential gain of +40% on today's $1.08. Buyers look set to stay in control over this stretch.
In 2035, DRMA is projected to trade between $1.13 and $2.76, averaging $1.70 — a potential gain of +58% from today's $1.08. That is up +13% on the projected 2034 average. Momentum favours further upside here.
Dermata Therapeutics, Inc.'s 2040 outlook centres on $1.76, within a $1.08 to $3.05 range. That is up +4% on the projected 2035 average. That marks a +63% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, DRMA could reach as high as $7.24, with a base case around $3.79 and support toward $2.05 — roughly +252% from $1.08. Momentum favours further upside here.
Investing $1,000 in DRMA today (≈ 930.232558 DRMA) could be worth
$3,523.41
+$2,523.41 (+252%) by 2050 · US Dollar
Based on the average projected DRMA price of $3.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DRMAwould be worth at today's price.
$1,000 invested in DRMA on Jul 31, 2025 (≈ 160.513643 DRMA) would be worth
$172.55
-$827.45 (-82.7%) today · 0.17× · US Dollar
Based on a DRMA entry price of $6.23 vs. today's $1.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.32 | $814.39 | -18.6% |
| 1 month ago | $1.38 | $778.99 | -22.1% |
| 3 months ago | $1.33 | $808.27 | -19.2% |
| 6 months ago | $2.02 | $532.18 | -46.8% |
| 1 year ago | $6.23 | $172.55 | -82.7% |
| All time (5.0y) ago | $12,456 | $0.09 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DRMA forecast.
Our base-case forecast reaches $2.10 around 2050.
Implied market cap at $2.10: $8.45M
The multi-year forecast projects a path of gradual upside with bullish sentiment emerging in the later years. In 2026 the average price is $1.18 with a neutral sentiment and 0% ROI. By 2027 the average rises to $1.28 with an 8.2% ROI, followed by $1.48 average and 25.8% ROI in 2028, and $1.62 average with 37.5% ROI in 2029.
In 2030 the forecast shows an average of $1.73 and a 46.7% ROI, strengthening further to a $1.66 average and 40.7% ROI in 2031, and $1.50 average with 27% ROI in 2032. The bullish trend continues with 2033 at $1.66 (40.3%), 2034 at $1.80 (52.2%), and 2035 at $2.05 (73.8%). By 2040 the average is projected at $2.10 with a 77.6% ROI, and by 2050 the average reaches $4.63 with a 292.7% ROI.
Overall, the longer-term view indicates meaningful upside potential, tempered by the inherent uncertainty of small-cap price movements and the variability of sector dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $1.73 with a max of $2.60 and an ROI of 46.7%. The sentiment is bullish.
The forecast starts neutral in 2026 with an avg of $1.18 and 0% ROI, then progresses to bullish years with an average of $1.73 in 2030 and a 46.7% ROI, culminating in an average of $4.63 and a 292.7% ROI by 2050.
Yes. The 2050 forecast lists an average of $4.63 and a max of $9.08, indicating that reaching $5 is within the stated range.
Current price is $1.18 and market cap is $4.75M.
The 30-day picture shows a bearish sentiment with RSI(14) at 40, SMA50 at $1.27, SMA200 at $1.91, support at $1.17, and resistance at $1.41; the 30-day range is $0.9573 to $1.45.
Dermata Therapeutics, Inc. Community Discussion
0Share your Dermata Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.